Tucatinib's Journey from Clinical Development to Clinical Practice: New Horizons for HER2-Positive Metastatic Disease and Promising Prospects for Brain Metastatic Spread

Metastatic breast cancer (BC) is the second most common cancer after lung cancer, associated with the development of brain metastases (BMs) [1]. As cancer research breakthroughs considerably improved survival of patients with advanced BC in the last decades, the incidence of BMs has also increased accordingly (Figure 1) [2]. Hence, new treatment options and therapeutic strategies are needed to ensure a survival advantage for patients with BMs. However, data about the efficacy of anti-cancer agents on BMs are limited.

Source: Cancer Treatment Reviews - August 22, 2023 Category: Cancer & Oncology Authors: Carmen Criscitiello, Chiara Corti, Michelino De Laurentiis, Giampaolo Bianchini, Barbara Pistilli, Saverio Cinieri, Lucio Castellan, Grazia Arpino, Pierfranco Conte, Francesco Di Meco, Alessandra Gennari, Valentina Guarneri, Luca Visani, Lorenzo Livi, Pao Tags: Anti-tumour Treatment Source Type: research